Disposition and metabolism of 14C-rifapentine in healthy volunteers

Drug Metabolism and Disposition

Volumn 26, Issue 8, 1998, Pages 732-738

  Reith, Kelly ^a   Keung, Anther ^b   Toren, Paul C ^b   Cheng, Lawrence ^b   Eller, Mark G ^b   Weir, Scott J ^b  

^a SANOFI   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

25 DEACETYLRIFAPENTINE; 3 FORMYL 25 DESACETYLRIFAPENTINE; 3 FORMYLRIFAPENTINE; CARBON 14; DRUG METABOLITE; ESTERASE; RIFAPENTINE; UNCLASSIFIED DRUG; CARBON; DIAGNOSTIC AGENT; DRUG DERIVATIVE; PLASMA PROTEIN; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOACTIVITY; ADOLESCENT; CHEMISTRY; ERYTHROCYTE; FECES; KIDNEY; METABOLISM; MIDDLE AGED; PROTEIN BINDING; URINE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; BLOOD PROTEINS; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ERYTHROCYTES; FECES; HUMANS; KIDNEY; MALE; MIDDLE AGED; PROTEIN BINDING; RIFAMPIN;

EID: 0031596346     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Acocella G (1978) Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 3:108-127.
2. Arioli V, Berti M, Carniti G, Randist E, Rossi E and Scotti R (1981) Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative. J Antibiot 34:1026-1032.
3. Assandri A, Cristina T and More L (1978) Physiological disposition of a series of rifamycins in rat: a comparative study. J Antibiot 31:894-901.
4. Assandri A, Ratti B and Cristina T (1984) Pharmacokinetics of rifapentine, a new long lasting rifamycin, in the rat, the mouse and the rabbit. J Antibiot 37:1066-1075.
5. 14C-rifabutin in animals and man. J Antimicrob Chemother 26:813-822.
6. Blashke TF and Skinner MH (1996) The clinical pharmacokinetics of rifabutin. Clin Infect Dis 22(Suppl 1):S15-S22.
7. Birmingham AT, Coleman AJ, Orme ML, Park BK, Pearson NJ, Short AH and Southgate PJ (1978) Antibacterial activity in serum and urine following oral administration in man of DL473 (a cyclopentyl derivative of rifampicin). Br J Clin Pharmacol 6:455P-456P.
8. Biya Y, Xikuam N, Lizhen Z and Fengying Z (1987) Absorption and elimination of cyclopentyl-rifamycin in human subjects. Chin J Tuberc Respir Dis 10:267-268.
9. Buniva G, Sassella D and Frigo GM (1983) Pharmacokinetics of rifapentine in man. Proc Int Congr Chemother 111:29-33.
10. Chan SL, Yew WW, Porter JHD, McAdam WJKP, Allen BW, Dickinson JM, Ellard GA and Mitchison DA (1994) Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals. Int J Antimicrob Agents 3:267-274.
11. Cocchiara G, Benedetti MS, Vicario GP, Ballabio M, Gioia B, Vioglio S and Vigevani A (1989) Urinary metabolites of rifabutin, a new antimycobacterial agent, in human volunteers. Xenobiotica 19:769-780.
12. Dickinson JM and Mitchison DA (1987) In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle 68:113-119.
13. Emary WB, Toren PC, Mathews B and Huh K (1998) Disposition and metabolism of rifapentine, a rifamycin antibiotic, in mice, rats, and monkeys. Drug Metab Dispos 26:725-731.
14. He X, Wang J, Liu X and Chen X (1996) High-performance liquid chromatography assay of rifapentine in human serum. J Chromatogr B 681:412-415.
15. Heifets LB, Lindholm-Levy PJ and Flory MA (1990) Bactericidal activity in vitro of various rifamycins against M. avium and M. tuberculosis. Am Rev Respir Dis 141:626-630.
16. Keung ACF, Miller TD, Green VI, Ames M, Eller MG and Weir SJ (1996) Bioavailability (BA) and food effect study of rifapentine in healthy adults. Pharm Res 12(Suppl):S419.
17. Leinweber F-J (1987) Possible physiological roles of carboxylic ester hydrolases. Drug Metab Rev 18:379-439.
18. Loos U, Musch E, Jensen JC, Mikrus G, Schwabe HK and Eichelbaum M (1985) Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochenschr 63:1205-1211.
19. Mor N, Simon B, Mezo N and Heifets L (1995) Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob Agents Chemother 39:2073-2077.
20. Qing Z, Yijan C and Yingyuan Z (1994) Clinical pharmacokinetic study on rifapentine. Chin J Antibiot 19:456-458.
21. Weber A, Opheim KE, Smith AL and Wong K (1983) High-pressure liquid chromatographic quantitation of rifampin and its two major metabolites in urine and serum. Rev Infect Dis 5(suppl 3):S433-S439.
22. Yates MD and Collins CH (1982) Comparison of the sensitivity of mycobacteria to the cyclopentyl rifamycin DL473 and rifamycin. J Antimicrob Chemother 10:147-150.
23. Zheng C, Yi L and Huiyan Z (1987) Pharmacokinetics of domestic rifapentine in patients with acute pulmonary infections. Chin J Antibiot 12:333-336.